Cytokinetics, Incorporated
CYTK
$77.22
$2.413.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -829.61M | -784.96M | -751.94M | -606.31M | -615.26M |
| Total Depreciation and Amortization | 11.20M | 10.13M | 9.65M | 9.38M | 9.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 325.20M | 300.45M | 301.44M | 174.73M | 151.60M |
| Change in Net Operating Assets | -30.64M | -35.63M | 7.93M | -4.72M | 56.16M |
| Cash from Operations | -523.85M | -510.01M | -432.93M | -426.92M | -398.00M |
| Capital Expenditure | -25.07M | -24.81M | -20.45M | -11.80M | -9.57M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 81.28M | 41.47M | 219.17M | 236.45M | -470.21M |
| Cash from Investing | 56.20M | 16.67M | 198.72M | 224.65M | -479.78M |
| Total Debt Issued | 729.46M | 729.46M | 729.46M | -- | -- |
| Total Debt Repaid | -413.36M | -413.51M | -413.71M | -11.39M | -11.57M |
| Issuance of Common Stock | 39.67M | 35.98M | 27.81M | 27.20M | 644.34M |
| Repurchase of Common Stock | -3.30M | -2.47M | -2.43M | -1.71M | -1.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 175.00M | 175.00M | 75.00M | 75.00M | 200.00M |
| Cash from Financing | 527.47M | 524.46M | 416.14M | 89.10M | 831.57M |
| Foreign Exchange rate Adjustments | -928.00K | -715.00K | -614.00K | -786.00K | -88.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.90M | 30.40M | 181.32M | -113.97M | -46.30M |